Select therapeutic use:

Arthritis/rheumatic disorders:

Indications for ILARIS:

Active Still's disease, including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA).

Adults and Children:

<2yrs: not established. Avoid injecting into scar tissue. Give as SC inj every 4 weeks. ≥2yrs (≥7.5kg): 4mg/kg; max 300mg.

Warnings/Precautions:

Do not start in patients with active infection; discontinue if serious infection develops. History of recurring infections or conditions that predispose to infection. Test for and treat TB before starting therapy. Discontinue if severe hypersensitivity reaction occurs. Patients should receive all recommended vaccines (eg, pneumococcal, influenza) prior to initiating therapy. Macrophage activation syndrome (esp. in Still's disease). Pregnancy. Nursing mothers.

Pharmacologic Class:

Interleukin-1beta blocker.

Interactions:

Concomitant TNF inhibitors, other IL-1 blockers, live vaccines: not recommended. Monitor warfarin, other agents with narrow therapeutic indexes; may need dose adjustments.

Adverse Reactions:

Nasopharyngitis, diarrhea, influenza, rhinitis, nausea, headache, bronchitis, gastroenteritis, pharyngitis, inj site reactions, weight increased, musculoskeletal pain, vertigo, abdominal pain; increased risk of infections, malignancies.

Generic Availability:

NO

How Supplied:

Single-dose vial—1

Miscellaneous immune disorders:

Indications for ILARIS:

Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children ≥4yrs of age including: Familial Cold Autoinflammatory Syndrome (FCAS); Muckle-Wells Syndrome (MWS). Treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF) in adults and children.

Adults and Children:

Avoid injecting into scar tissue. CAPS: Give as SC inj every 8 weeks. <4yrs: not established. ≥4yrs: (≥15–≤40kg): 2mg/kg; children (15–40kg) with inadequate response: may increase to 3mg/kg; (>40kg): 150mg. TRAPS, HIDS/MKD, FMF: Give as SC inj every 4 weeks. <2yrs: not recommended. ≥2yrs: (≤40kg): 2mg/kg, may increase to 4mg/kg every 4 weeks if inadequate response; (>40kg): 150mg, may increase to 300mg every 4 weeks if inadequate response.

Warnings/Precautions:

Do not start in patients with active infection; discontinue if serious infection develops. History of recurring infections or conditions that predispose to infection. Test for and treat TB before starting therapy. Discontinue if severe hypersensitivity reaction occurs. Patients should receive all recommended vaccines (eg, pneumococcal, influenza) prior to initiating therapy. Macrophage activation syndrome (esp. in Still's disease). Pregnancy. Nursing mothers.

Pharmacologic Class:

Interleukin-1beta blocker.

Interactions:

Concomitant TNF inhibitors, other IL-1 blockers, live vaccines: not recommended. Monitor warfarin, other agents with narrow therapeutic indexes; may need dose adjustments.

Adverse Reactions:

Nasopharyngitis, diarrhea, influenza, rhinitis, nausea, headache, bronchitis, gastroenteritis, pharyngitis, inj site reactions, weight increased, musculoskeletal pain, vertigo, abdominal pain; increased risk of infections, malignancies.

Generic Availability:

NO

How Supplied:

Single-dose vial—1